RhoVac"s CEO Anders Ljungqvist will present the company"s status at the BioStock Life Science Summit on October 25th at Medicon Village in Lund. The program and registration for this event is at https://www.summit.biostock.se/. 

For more information, please contact:

Anders Ljungqvist – CEO, RhoVac AB

Phone: +45 4083 2365

E-mail: alj@rhovac.com

About RhoVac AB

RhoVac AB conducts research and development of immunotherapeutic drugs. The company"s main focus is the development of a therapeutic cancer vaccine with the potential to prevent or limit metastasis in cancer. RhoVac"s top-line results from the  clinical phase I / II study has been published I August 2018. RhoVac has its head office at Medicon Village in Lund, Sweden. The research has been conducted since 2007 primarily at the University Hospital in Herlev, Denmark, by a world-class research team in its niche. RhoVac is listed on Spotlight StockMarket, Sweden, a Multilateral Trading Facility (MTF), since March 2016. The share is traded under the ticker RHOVAC. Read more at www.rhovac.com.